Mayo Clinic study finds prophylactic mastectomy reduces breast cancer risk in highest-risk group of women -- carriers of BRCA1 and BRCA2 mutations

November 06, 2001

ROCHESTER, MINN. -- A Mayo Clinic study shows that prophylactic removal of both breasts reduces the risk of a subsequent breast cancer by 89.5 percent to 100 percent in women known to be carriers of mutations in the BRCA1 and BRCA2 susceptibility genes.

The study, published in the Nov. 7, 2001, issue of the Journal of the National Cancer Institute followed 26 high-risk women, identified with altered BRCA1 and BRCA2 breast cancer susceptibility genes. All of these women had previously undergone surgery to have their breasts removed. During the period of follow-up thus far -- averaging 13.4 years -- none of these women have developed breast cancer.

"Calculations predict that six to nine breast cancers should have developed in this group of carriers without prophylactic surgery," says Lynn Hartmann, M.D., a Mayo Clinic oncologist and lead researcher on this study. "That translates into a risk reduction of 89.5 percent to 100 percent for bilateral prophylactic mastectomy."

This study is the latest in ongoing research at Mayo Clinic about prophylactic mastectomy and subsequent breast cancer risk. The original research group included 214 women with a strong family history of breast cancer who had previously had prophylactic mastectomy. Women in this surgical group were compared with their sisters who had not had prophylactic mastectomy. That study showed that prophylactic mastectomy reduced the risk of subsequent breast cancer by approximately 90 percent.

For this most recent study, investigators worked to determine the underlying BRCA1 and BRCA2 status of these high-risk women. Blood samples were obtained from 176 of the 214 women. Twenty-six of these women were identified to have altered BRCA1 and BRCA2 genes and they formed the study group for this JNCI report.

"Our previous study had shown that prophylactic mastectomy reduced subsequent breast cancer risk substantially in women who had the procedure because of a strong family history," Dr. Hartmann says. "But a question remained: Would the procedure be able to reduce risk in the highest risk group -- namely BRCA1 and BRCA2 carriers? Our current data support that it can, although ours is a relatively small group of carriers. These data complement the Dutch study published this past summer, which showed similar risk reduction in a larger number of carriers who had had prophylactic mastectomy. Their study had a relatively short period of follow-up, however."
-end-
Contact: Mary Lawson
507-284-5005 (days)
507-284-2511 (evenings)
e-mail: newsbureau@mayo.edu

Mayo Clinic

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.